 |
allogeneic ex-vivo generated CD56+CD3-natural killer cells from CD34+ umbilical cord blood progenitor cells |
|---|---|
| Trade Name | |
| Orphan Indication | Acute myeloid leukemia |
| USA Market Approval | USA |
| USA Designation Date | 2016-04-20 00:00:00 |
| Sponsor | IPD-Therapeutics BV;(Trading as Glycostem-Therapeutics), Molenstraat 110 5342 CC Oss; |
